Myriad kept by JMP at market outperform

Myriad Genetics Inc. was retained by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $25 per share following fiscal fourth-quarter results. Myriad shares Wednesday were up $0.12, or 0.66%, at $18.27 on volume of 1,576,357 shares versus the three-month running average of 269,257 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.